Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q2 FY24 Earnings Presentation
21 slides from Balaxi Pharmaceuticals's earnings presentation
Slide 1: Branded IPR-driven Pharma Player in Frontier Markets
Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation
Slide 2: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual
Slide 3: Contents
Contents 04 Corporate Snapshot 14 Financial Highlights 20 Strategic Roadmap 3
Slide 4: Bridging the Supply Gap in Frontier Markets
Bridging the Supply Gap in Frontier Markets Branded IPR-based pharma Presence in OTC segments including company strong branded generics portfolio Frontier markets leadership in Targeting top-2 position in each Latin America and Africa geography Vast portfolio across diverse Backed by deep distributi
Slide 5: Successful Produce, Stock, Sell Business Model
Successful Produce, Stock, Sell Business Model Established operations: Guatemala (Latin America), Dominican Republic (Caribbean) and Expansion initiated: Markets Angola (Africa) Nicaragua, Ecuador, Chile (Latin America) New operations: Hondurus, El Salvador and Central African Republic 855 product r
Slide 6: Key Success Factors
Key Success Factors Market Selection Methodology Focus on countries with high-potential economic growth framework Identify non-English speaking countries with similar characteristics Low competitive intensity and potential to establish top-2 position On-ground feedback mechanism allows deep
Slide 7: Transition from "Asset Light" to "Asset Right"
Transition from “Asset Light” to “Asset Right” Marketing and Market Research Product Product Manufacturing Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi is moving its business model from ‘Asset Light’ to ‘Asset Right’
Slide 8: Investment in Manufacturing Facilities
Investment in Manufacturing Facilities Setting up its first pharmaceutical formulation manufacturing unit General Oral Solid Dosage (OSD) and Liquid Injection formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply chain Production
Slide 9: Global Footprint
Global Footprint China India Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9
Slide 10: Key Milestones
Key Milestones Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMP certified warehouse in Guatemala, based in India manufacturers in
Slide 11: Corporate Structure
Corporate Structure Balaxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Healthcare Healthcare Balaxi Healthcare Healthcare Healthcare Healthcare Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Central African Angola LDA SRL (WOS) S.A
Slide 12: Experienced Board of Directors
Experienced Board of Directors Ashish Maheshwari Minoshi Maheshwari Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich experience with Balaxi exp
Slide 13: Dynamic Leadership Team
Dynamic Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associat
Slide 14: Financial Highlights
Balaxi FINANCIAL HIGHLIGHTS MIM emg
Slide 15: Management's Comments
Management’s Comments “During the quarter, we took various corrective measures to manage the exceptionally challenging situation that arose in the previous quarter due to unprecedented economic chaos in our oldest and biggest market of Angola, where local currency weakened in record time beyond the
Slide 16: Quarterly Financial Performance
Quarterly Financial Performance Particulars (INR Crore) Q2FY24 Q2FY23 YoY Revenue 54.72 86.38 (36.6%) Gross Profit 25.60 36.04 (29.0%) Gross Margin % 46.8% 41.7% +510 bps EBITDA* 16.41 14.75 +11.2% EBITDA Margin % 29.9% 17.1% +1280 bps Profit After Tax* 14.43 15.49 (6.8%) PAT Margin % 26.4% 17.9% +8
Slide 17: Pharma Product Mix – Q2 FY24
Pharma Product Mix – Q2 FY24 Geographies Products Shareholders’ Debt Fixed Assets Working Capital Funds 29% 45% Africa* Branded 55% LATM** Generics 71% Dosage Forms Therapeutic Areas 8% Tablets 26% Antibiotics Injectables Analgesic 20% 45% Liquids 22% 53% Anti-malaria Capsules 19% Others 10% Others
Slide 18: Historical Financial Performance (Consolidated): FY23
Historical Financial Performance (Consolidated): FY23 Particulars (INR Crore) FY23 FY22 YoY Revenue 336.43 279.39 +20.4% Gross Profit 134.01 83.79 +59.9% Gross Margin % 39.8% 30.0% +980 bps EBITDA 59.17 55.18 +7.2% EBITDA Margin % 17.6% 19.7% (210 bps) Profit After Tax 45.96 47.66 (3.6%) PAT Margin
Slide 19: Pharma Product Mix – FY23
Pharma Product Mix – FY23 Geographies Products Shareholders’ Debt Fixed Assets Working Capital 40% Funds 37% Africa* Branded LATAM** Generics 60% 63% Dosage Forms Therapeutic Areas 10% Tablets Antibiotics 33% 41% Injectables Analgesic 20% 45% Liquids Anti-malaria Capsules Others 11% Others 7% 19% 14
Slide 20: Core Strategy: Enter, Expand & Excel
Core Strategy: Enter, Expand & Excel Balaxi in 2020: Business Consolidation Presence across Angola, Guatemala and Dominican Republic Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-23: Expansion into New Geographies Aim to cap
Slide 21: Thank You
Plot No. 409, H.No. 8-2-293, 2nd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Telangana CIN: L25191TG1942PLC121598 Company Investor Relations contact Sunny Purohit +91-40-2355-5300 sunny@balaxi.com www.balaxipharma.in BALAXI Thank You BALAXI:IN
Balaxi Pharmaceuticals — Q2 FY24 Earnings Presentation on 6ix